[go: up one dir, main page]

MX2016008518A - Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo. - Google Patents

Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo.

Info

Publication number
MX2016008518A
MX2016008518A MX2016008518A MX2016008518A MX2016008518A MX 2016008518 A MX2016008518 A MX 2016008518A MX 2016008518 A MX2016008518 A MX 2016008518A MX 2016008518 A MX2016008518 A MX 2016008518A MX 2016008518 A MX2016008518 A MX 2016008518A
Authority
MX
Mexico
Prior art keywords
region
rna
micro
artificial
gene expression
Prior art date
Application number
MX2016008518A
Other languages
English (en)
Other versions
MX387332B (es
Inventor
Ohgi Tadaaki
Aoki Eriko
Kuroda Masahiko
OHNO Shinichiro
Yoshida Yasuhiko
Kato Shiori
Original Assignee
Bonac Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bonac Corp filed Critical Bonac Corp
Publication of MX2016008518A publication Critical patent/MX2016008518A/es
Publication of MX387332B publication Critical patent/MX387332B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención provee un micro-ARN de tipo concordante artificial novedoso que utiliza micro-ARN. El micro-ARN de tipo concordante artificial es un ácido nucleico de cadena sencilla que comprende una región X y una región Y y está configurado de tal manera que: el extremo 3' de la región X y el extremo 5' de la región Y están conectados por medio de una región enlazadora que tiene una estructura no nucleotídica; la región X comprende una secuencia de cadena guía de un micro-ARN maduro; y la región Y es un ácido nucleico de cadena sencilla que comprende una secuencia que es totalmente complementaria a la región X. Este micro-ARN de tipo concordante artificial hace posible inhibir la expresión de un gen objetivo.
MX2016008518A 2013-12-27 2014-12-27 Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo. MX387332B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013273033 2013-12-27
PCT/JP2014/084724 WO2015099187A1 (ja) 2013-12-27 2014-12-27 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途

Publications (2)

Publication Number Publication Date
MX2016008518A true MX2016008518A (es) 2017-01-26
MX387332B MX387332B (es) 2025-03-18

Family

ID=53479025

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016008518A MX387332B (es) 2013-12-27 2014-12-27 Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo.

Country Status (13)

Country Link
US (1) US10934542B2 (es)
EP (1) EP3088525A4 (es)
JP (2) JP6425142B2 (es)
KR (1) KR102357337B1 (es)
CN (2) CN106068324B (es)
AU (1) AU2014370829B2 (es)
BR (1) BR112016014986A2 (es)
CA (1) CA2935022A1 (es)
IL (2) IL246395B (es)
MX (1) MX387332B (es)
RU (1) RU2697094C2 (es)
SG (3) SG10201805087VA (es)
WO (1) WO2015099187A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2857513A4 (en) 2012-05-26 2016-05-25 Bonac Corp Single-stranded nucleic acid molecule controlling the expression of a gene transporter
US10612020B2 (en) 2013-12-26 2020-04-07 Tokyo Medical University Artificial mimic miRNA for controlling gene expression, and use of same
BR112016014986A2 (pt) 2013-12-27 2018-01-23 Bonac Corporation mirna tipo correspondência artificial, composição e método para suprimir expressão de um gene alvo, composição farmacêutica, método para tratar uma doença, e, ácido nucleico de fita única
RU2740032C2 (ru) 2014-12-27 2020-12-30 Бонак Корпорейшн ВСТРЕЧАЮЩИЕСЯ В ПРИРОДЕ миРНК ДЛЯ КОНТРОЛИРОВАНИЯ ЭКСПРЕССИИ ГЕНОВ И ИХ ПРИМЕНЕНИЕ
HK1244031A1 (en) 2015-03-27 2018-07-27 Bonac Corporation Single-chain nucleic acid molecule having delivery function and gene expression control ability
JPWO2016167366A1 (ja) * 2015-04-17 2018-04-05 国立大学法人 東京大学 眼疾患治療剤
CA3002786C (en) * 2015-10-30 2021-09-07 Bonac Corporation Composition stably containing single-stranded nucleic acid molecule that suppresses expression of tgf-.beta.1 gene
BR112018015164A2 (pt) 2016-01-26 2018-12-26 Nissan Chemical Corp oligonucleotídeo de fita simples
KR102255995B1 (ko) * 2016-01-30 2021-05-25 가부시키가이샤 보낙 인공 단일 가이드 rna 및 이의 용도
CA3052801A1 (en) * 2017-02-06 2018-08-09 Nissan Chemical Corporation Single-stranded oligonucleotide
WO2018155487A1 (ja) * 2017-02-21 2018-08-30 株式会社ボナック 核酸含有ｄｐｉ用粉末製剤及びその用途
TWI830718B (zh) * 2018-02-09 2024-02-01 日商住友化學股份有限公司 核酸分子之製造方法
US20210054377A1 (en) 2018-03-20 2021-02-25 Tokyo Institute Of Technology Antisense oligonucleotide reduced in toxicity

Family Cites Families (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE873543C (de) 1942-10-28 1953-04-16 Basf Ag Verfahren zur Herstellung von hydroxyl- bzw. sulfhydryl-gruppenhaltigen Dicarbaminsaeureestern
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4550163A (en) 1979-02-05 1985-10-29 Abbott Laboratories Ligand analog-irreversible enzyme inhibitor conjugates
US20030232355A1 (en) 1992-05-22 2003-12-18 Isis Pharmaceuticals, Inc. Double-stranded peptide nucleic acids
US5631148A (en) 1994-04-22 1997-05-20 Chiron Corporation Ribozymes with product ejection by strand displacement
GB9621367D0 (en) 1996-10-14 1996-12-04 Isis Innovation Chiral peptide nucleic acids
US6197557B1 (en) 1997-03-05 2001-03-06 The Regents Of The University Of Michigan Compositions and methods for analysis of nucleic acids
EP1013770A1 (en) 1998-12-23 2000-06-28 Université Louis Pasteur de Strasbourg Non-viral transfection vector
FR2790757B1 (fr) 1999-03-09 2003-08-01 Bioalliance Pharma Oligonucleotides contenant une sequence antisens stabilises par une structure secondaire et compositions pharmaceutiques les contenant.
US6852334B1 (en) 1999-04-20 2005-02-08 The University Of British Columbia Cationic peg-lipids and methods of use
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
US6962906B2 (en) 2000-03-14 2005-11-08 Active Motif Oligonucleotide analogues, methods of synthesis and methods of use
EP1748078B1 (en) 2001-03-09 2011-01-19 Boston Probes, Inc. Methods, kits and compositions of combination oligomers
CA2526831C (en) 2001-05-18 2012-07-31 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
JP2005508634A (ja) 2001-10-29 2005-04-07 マクギル・ユニヴァーシティ 非環式リンカー含有オリゴヌクレオチド及びその用途
WO2003072745A2 (en) 2002-02-22 2003-09-04 Eshleman James R Antigene locks and therapeutic uses thereof
US20040248296A1 (en) 2002-03-20 2004-12-09 Beresford Paul J. HIV therapeutic
EP1527176B2 (en) 2002-08-05 2017-03-22 Silence Therapeutics GmbH Further novel forms of interfering rna molecules
AU2003256857A1 (en) 2002-08-08 2004-02-25 Dharmacon, Inc. Short interfering rnas having a hairpin structure containing a non-nucleotide loop
US6936651B2 (en) 2002-12-17 2005-08-30 E. I. Du Pont De Nemours And Company Compatibility improvement in crystalline thermoplastics with mineral fillers
CA2488224A1 (en) 2003-04-03 2004-10-21 Alnylam Pharmaceuticals, Inc. Irna conjugates
US20050053979A1 (en) 2003-06-12 2005-03-10 Livak Kenneth J. Combinatorial nucleobase oligomers comprising universal base analogues and methods for making and using same
US8106180B2 (en) 2003-08-07 2012-01-31 Whitehead Institute For Biomedical Research Methods and products for expression of micro RNAs
ATE532865T1 (de) 2003-09-30 2011-11-15 Anges Mg Inc Klammerartiges oligonukleotid und dieses enthaltender arzneistoff
JP2007508030A (ja) 2003-10-14 2007-04-05 カーネル・バイオファーマ・インコーポレイテッド 血液脳関門を介してｐｎａを送達するための２相ｐｎａ結合体
US20050209141A1 (en) 2003-10-17 2005-09-22 Silver Randi B Mast cell-derived renin
US7615618B2 (en) 2004-06-30 2009-11-10 Alnylam Pharmaceuticals, Inc. Oligonucleotides comprising a non-phosphate backbone linkage
US8030284B2 (en) 2004-08-23 2011-10-04 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
WO2006022325A1 (ja) 2004-08-26 2006-03-02 Nippon Shinyaku Co., Ltd. ガラクトース誘導体、薬物担体及び医薬組成物
US20090264501A9 (en) * 2004-08-31 2009-10-22 Sylentis S.A. Methods and Compositions to Inhibit P2x7 Receptor Expression
CA2583690C (en) 2004-10-12 2016-04-05 The Rockefeller University Microrna constructs for the suppression of the expression of targeted genes or the down regulation of targeted genes and methods therefore
AU2005333165B2 (en) * 2004-11-12 2012-07-19 Asuragen, Inc. Methods and compositions involving miRNA and miRNA inhibitor molecules
JP2008526213A (ja) 2004-12-30 2008-07-24 トッド エム． ハウザー， 自己保護オリゴヌクレオチドを使用する、遺伝子発現を調節するための組成物および方法
KR20080106437A (ko) 2006-03-01 2008-12-05 니뽄 신야쿠 가부시키가이샤 갈락토스 유도체, 약물 담체 및 의약 조성물
CA2651042A1 (en) 2006-05-05 2007-12-13 Isis Pharmaceuticals, Inc. Compounds and methods for modulating expression of sglt2
EP3872179A1 (en) * 2006-05-11 2021-09-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the pcsk9 gene
EP2029597A4 (en) 2006-05-31 2011-11-23 Univ California purine analogs
EP1890152A1 (en) 2006-08-14 2008-02-20 Charite Universitätsmedizin-Berlin Determination of renin/prorenin receptor activity
JP2008220366A (ja) 2007-02-16 2008-09-25 National Institute Of Advanced Industrial & Technology 修飾型ｐｎａ／ｒｎａ複合体
JP5145557B2 (ja) 2007-03-01 2013-02-20 財団法人ヒューマンサイエンス振興財団 マイクロｒｎａを有効成分として含有する腫瘍増殖抑制剤、および癌治療用医薬組成物
CA2681323A1 (en) 2007-03-21 2008-09-25 Brookhaven Science Associates, Llc Combined hairpin-antisense compositions and methods for modulating expression
CN101121934B (zh) 2007-04-11 2011-12-07 哈尔滨医科大学 多靶点miRNA反义核苷酸的制备方法
AU2008247427A1 (en) 2007-05-03 2008-11-13 Rosetta Inpharmatics Llc Compositions comprising miR34 therapeutic agents for treating cancer
JP5296328B2 (ja) 2007-05-09 2013-09-25 独立行政法人理化学研究所 １本鎖環状ｒｎａおよびその製造方法
US20090123501A1 (en) 2007-05-17 2009-05-14 Baylor College Of Medicine Inhibition of the sh2-domain containing protein tyr-phosphatase, shp-1, to enhance vaccines
US9353368B2 (en) 2007-05-23 2016-05-31 Ge Healthcare Dharmacon, Inc. Micro-RNA scaffolds and non-naturally occurring micro-RNAs
AU2008260103B2 (en) 2007-05-31 2014-04-03 University Of Iowa Research Foundation Reduction of off-target RNA interference toxicity
US20110212075A1 (en) 2007-06-25 2011-09-01 Siemens Aktiengesellschaft Screening method for polymorphic markers in htra1 gene in neurodegenerative disorders
ES2617877T3 (es) * 2007-08-27 2017-06-20 1Globe Health Institute Llc Composiciones de ARN interferente asimétrico y uso de las mismas
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
EP2209894B1 (en) 2007-10-12 2015-06-03 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Method for opening tight junctions
TW200927177A (en) 2007-10-24 2009-07-01 Nat Inst Of Advanced Ind Scien Lipid-modified double-stranded RNA having potent RNA interference effect
AR069328A1 (es) 2007-11-15 2010-01-13 Alcon Mfg Ltd Liberacion de rna interferente corto o sirna, intermediada por receptor de lipoproteina de baja densidad
JP2011504730A (ja) 2007-11-29 2011-02-17 蘇州瑞博生物技術有限公司 標的遺伝子の発現を干渉する複合体分子およびその合成方法
AU2008333811B2 (en) 2007-12-04 2014-05-01 Alnylam Pharmaceuticals, Inc. Carbohydrate conjugates as delivery agents for oligonucleotides
US20110159586A1 (en) 2007-12-07 2011-06-30 Halo-Bio Rnai Therapeutics, Inc. Compositions and methods for modulating gene expression using asymmetrically-active precursor polynucleotides
US20110055965A1 (en) 2008-02-15 2011-03-03 Hiroshi Abe Cycle single-stranded nucleic acid complex and method for producing the same
ES2605618T3 (es) 2008-03-31 2017-03-15 National Institute Of Advanced Industrial Science And Technology ARN de doble cadena, modificado con lípidos con elevado efecto de interferencia por ARN
WO2009126563A1 (en) 2008-04-11 2009-10-15 The University Of North Carolina At Chapel Hill Methods and compositions for the regulation of microrna processing
WO2009143619A1 (en) 2008-05-27 2009-12-03 Chum Methods of treating or preventing obesity and obesity-related hypertension
US20100179213A1 (en) 2008-11-11 2010-07-15 Mirna Therapeutics, Inc. Methods and Compositions Involving miRNAs In Cancer Stem Cells
WO2010058824A1 (ja) 2008-11-19 2010-05-27 国立大学法人岐阜大学 間葉系細胞の分化を調節するための薬剤及びその利用
WO2010111503A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE HIGH AFFINITY IGE RECEPTOR ALPHA CHAIN (FCεRLα) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010141511A2 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
US8871730B2 (en) * 2009-07-13 2014-10-28 Somagenics Inc. Chemical modification of short small hairpin RNAs for inhibition of gene expression
US20120258104A1 (en) 2009-07-22 2012-10-11 Cenix Bioscience Gmbh Delivery System and Conjugates For Compound Delivery Via Naturally Occurring Intracellular Transport Routes
US9096850B2 (en) 2009-08-24 2015-08-04 Sirna Therapeutics, Inc. Segmented micro RNA mimetics
US20110052666A1 (en) 2009-09-03 2011-03-03 Medtronic, Inc. Compositions, Methods, and Systems for SIRNA Delivery
WO2011055888A1 (en) 2009-11-06 2011-05-12 Chung-Ang University Industry-Academy Cooperation Foundtion Nanoparticle-based gene delivery systems
EP2512449B1 (en) 2009-12-18 2019-08-07 The University of British Columbia Methods and compositions for delivery of nucleic acids
CA2784547A1 (en) 2009-12-23 2011-06-30 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Influenza targets
BR112012015755B1 (pt) 2009-12-23 2021-06-22 Novartis Ag Lipídeo furtivo, e composição
KR101852210B1 (ko) 2010-03-24 2018-04-25 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
CN101845071B (zh) 2010-03-25 2012-02-01 北京欧凯纳斯科技有限公司 一种2’或3’偶联氨基酸的核苷衍生物、其制备方法及应用
JP5555940B2 (ja) 2010-04-14 2014-07-23 国立大学法人佐賀大学 増殖糖尿病網膜症の検出方法および予防・治療剤のスクリーニング方法
WO2011132672A1 (ja) 2010-04-19 2011-10-27 独立行政法人理化学研究所 機能性核酸の安定化法
ES2699630T3 (es) 2010-04-23 2019-02-12 Cold Spring Harbor Laboratory Novedosos ARNhc diseñados estructuralmente
ES2670017T3 (es) 2010-07-08 2018-05-29 Bonac Corporation Molécula de ácido nucleico de cadena simple para el control de la expresión de genes
US8785121B2 (en) 2010-07-08 2014-07-22 Bonac Corporation Single-stranded nucleic acid molecule for controlling gene expression
WO2012012676A2 (en) 2010-07-22 2012-01-26 The University Of North Carolina At Chapel Hill Use of mir-29 for cell protection
KR101894702B1 (ko) 2010-08-03 2018-09-04 가부시키가이샤 보낙 함질소 지환식 골격을 갖는 일본쇄 핵산 분자
US8691782B2 (en) 2010-08-03 2014-04-08 Bonac Corporation Single-stranded nucleic acid molecule having nitrogen-containing alicyclic skeleton
ES2908978T3 (es) 2010-08-31 2022-05-04 Sirna Therapeutics Inc Nuevas entidades químicas simples y métodos para la administración de oligonucleótidos
WO2012074038A1 (ja) 2010-12-02 2012-06-07 第一三共株式会社 修飾１本鎖ポリヌクレオチド
CN102559666B (zh) 2010-12-18 2013-12-25 中国科学院上海生命科学研究院 抑制植物病毒的人工miRNA及其构建和用途
WO2012106591A1 (en) 2011-02-03 2012-08-09 Mirna Therapeutics, Inc. Synthetic mimics of mir-34
CN102784398B (zh) 2011-05-16 2014-06-18 南京大学 内皮抑素作为递送系统和化学合成的rna干扰分子组成的组合物及应用
WO2012161124A1 (ja) 2011-05-20 2012-11-29 国立大学法人愛媛大学 マイクロｒｎａ又はその発現系を含む組成物
EP2527440A1 (en) 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
JP2013055913A (ja) 2011-09-09 2013-03-28 Bonac Corp 遺伝子発現制御のための一本鎖ｒｎａ分子
WO2013077446A1 (ja) 2011-11-26 2013-05-30 株式会社ボナック 遺伝子発現制御のための一本鎖核酸分子
JP2013153736A (ja) 2012-01-07 2013-08-15 Bonac Corp ペプチド骨格を有する一本鎖核酸分子
CN104039961A (zh) 2012-01-07 2014-09-10 株式会社博纳克 具有氨基酸骨架的单链核酸分子
CN104271742B (zh) 2012-03-04 2018-06-05 株式会社博纳克 微小rna抑制剂
AR090905A1 (es) 2012-05-02 2014-12-17 Merck Sharp & Dohme Conjugados que contienen tetragalnac y peptidos y procedimientos para la administracion de oligonucleotidos, composicion farmaceutica
EP2857513A4 (en) 2012-05-26 2016-05-25 Bonac Corp Single-stranded nucleic acid molecule controlling the expression of a gene transporter
JP6510485B2 (ja) 2013-03-15 2019-05-08 オハイオ・ステイト・イノベーション・ファウンデーション Ｐｒｍｔ５インヒビターおよびそれらの使用方法
KR102365809B1 (ko) 2013-05-22 2022-02-23 알닐람 파마슈티칼스 인코포레이티드 Ｔｍｐｒｓｓ6 조성물 및 이의 사용 방법
WO2015093495A1 (ja) 2013-12-16 2015-06-25 株式会社ボナック ＴＧＦ－β１遺伝子発現制御のための一本鎖核酸分子
US10612020B2 (en) 2013-12-26 2020-04-07 Tokyo Medical University Artificial mimic miRNA for controlling gene expression, and use of same
JP6492014B2 (ja) 2013-12-27 2019-03-27 株式会社ボナック 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
BR112016014986A2 (pt) 2013-12-27 2018-01-23 Bonac Corporation mirna tipo correspondência artificial, composição e método para suprimir expressão de um gene alvo, composição farmacêutica, método para tratar uma doença, e, ácido nucleico de fita única
WO2015161255A1 (en) 2014-04-18 2015-10-22 Board Of Regents Of The Nevada System Of Higher Education, On Behalf Of The University Of Nevada, Reno Methods for enhancing or decreasing the levels of mir124 and mir29 in subjects with muscular dystrophy
RU2740032C2 (ru) 2014-12-27 2020-12-30 Бонак Корпорейшн ВСТРЕЧАЮЩИЕСЯ В ПРИРОДЕ миРНК ДЛЯ КОНТРОЛИРОВАНИЯ ЭКСПРЕССИИ ГЕНОВ И ИХ ПРИМЕНЕНИЕ
HK1244031A1 (en) 2015-03-27 2018-07-27 Bonac Corporation Single-chain nucleic acid molecule having delivery function and gene expression control ability
RU2718984C2 (ru) 2015-12-29 2020-04-15 Нэшнл Юниверсити Корпорейшн Хоккайдо Юниверсити Одноцепочечная молекула нуклеиновой кислоты, ингибирующая экспрессию гена проренина или гена рецептора проренина, и ее применение

Also Published As

Publication number Publication date
IL271715B (en) 2022-03-01
RU2016130611A (ru) 2018-01-31
US20160319282A1 (en) 2016-11-03
CN112646812A (zh) 2021-04-13
CN106068324B (zh) 2020-12-29
IL271715A (en) 2020-02-27
RU2697094C2 (ru) 2019-08-12
CN106068324A (zh) 2016-11-02
KR102357337B1 (ko) 2022-01-28
IL246395B (en) 2020-01-30
JP2018145199A (ja) 2018-09-20
SG11201605247XA (en) 2016-08-30
JP6425142B2 (ja) 2018-11-21
WO2015099187A1 (ja) 2015-07-02
KR20160121510A (ko) 2016-10-19
SG10201805087VA (en) 2018-07-30
IL246395A0 (en) 2016-08-31
CA2935022A1 (en) 2015-07-02
EP3088525A4 (en) 2017-08-09
MX387332B (es) 2025-03-18
AU2014370829B2 (en) 2021-03-11
JPWO2015099187A1 (ja) 2017-03-23
RU2016130611A3 (es) 2018-08-27
US10934542B2 (en) 2021-03-02
SG10201913570XA (en) 2020-03-30
JP6653889B2 (ja) 2020-02-26
AU2014370829A1 (en) 2016-08-11
EP3088525A1 (en) 2016-11-02
BR112016014986A2 (pt) 2018-01-23

Similar Documents

Publication Publication Date Title
MX2016008518A (es) Micro-acido ribonucleico (micro-arn) concordante artificial para controlar la expresion genetica y uso del mismo.
NZ630800A (en) Methods of preparing substituted nucleotide analogs
CY1119491T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της εκφρασης του γονιδιου alas1
AR114027A2 (es) Construcciones de adn recombinante y métodos para modular la expresión de un gen diana
BR112016004091A2 (pt) métodos e composições para tratamento guiado por rna de infecção por hiv
AR079883A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
EA201890999A1 (ru) Вакцина против вируса простого герпеса
AR079882A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
BR112012015740A2 (pt) anticorpos de anti-flt3 e metodos de uso dos mesmos
ES2721936T3 (es) Regulación de la expresión genética mediada por las nucleasas
BRPI0819526B8 (pt) Sequência de ácido nucleico de precursor de mirna artificial, construção recombinante e método para reduzir a expressão de uma sequência alvo
EA202191537A1 (ru) Композиции и способы ингибирования экспрессии генов вируса гепатита в
AR079881A1 (es) Plantas tolerantes a herbicidas inhibidores de las hppd
CY1116987T1 (el) Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις
MX390699B (es) Composiciones y metodos para inhibicion de genes para apolipoproteina c-iii (apoc3).
CY1120682T1 (el) Ενωσεις για την προστασια κυτταρων
UA115311C2 (uk) Геміфумарат тенофовіру алафенаміду
AU2011356210A8 (en) Novel fucosyltransferases and their applications
MX2016010675A (es) Compuestos condensados de [1,4]diazepina como inhibidores de produccion de la autotaxina (atx) y acido lisofosfatidico (lpa).
AU2007240448A8 (en) Methods and compositions for expressing negative-sense viral RNA in canine cells
AR070326A1 (es) Vectores de closterovirus y metodos relacionados
CL2018000158A1 (es) Composiciones y métodos para inhibir la expresión del gen alas1 (divisional de solicitud 20160772)
MX2017008587A (es) Mirna natural para controlar la expresion de gen y uso del mismo.
CO2017006736A2 (es) Supresión de arni parental de gen hunchback para el control de las plagas de hemípteros
CO2017009163A2 (es) Moléculas de ácido nucleico de arn polimerasa ii33 para el control de plagas de insectos